Archive · 4 Sep 2026
New Zealand Approves Supervised MDMA Therapy for Severe PTSD
New Zealand will let two psychiatrists use medical-grade MDMA to help some adults with severe PTSD.
PTSD can happen after very frightening or dangerous events.
The medicine will not be given to people to use at home.
Instead, patients will take it in a controlled clinic while receiving psychotherapy.
A specially authorized psychiatrist will supervise the treatment.
Patients must be at least 18 years old.
New Zealand is the second country to approve this kind of PTSD treatment, after Australia.
Supporters say MDMA may help people who have not improved enough with existing treatments.
In the United States, officials said more evidence was needed about whether the treatment is safe and effective.
Medsafe approved two psychiatrists to prescribe pharmaceutical-grade MDMA for adults with severe PTSD.
New Zealand is the second country to approve MDMA treatment for PTSD, after Australia in 2023.
The treatment must combine MDMA with psychotherapy in a controlled clinical setting.
Patients must be at least 18, and they will not receive MDMA to take home.
U.S. clinical trials continue after the FDA rejected medicinal MDMA approval in 2024 over insufficient safety and effectiveness evidence.
- Who
- Two New Zealand psychiatrists were approved to prescribe pharmaceutical-grade MDMA to patients aged 18 or older with severe PTSD.
- What
- New Zealand approved supervised MDMA-assisted therapy combined with psychotherapy for severe PTSD.
- When
- The approval was announced Friday; Australia approved similar use in 2023, while the United States rejected medicinal approval in 2024.
- Where
- Treatment will take place in controlled clinical settings in New Zealand.
- Why
- Supporters say PTSD is difficult to treat and that MDMA-assisted therapy could expand access to innovative treatment options.
Supporters of supervised access
Caution over evidence and safety
Potential effectiveness
Supporters of supervised access
Deputy Prime Minister David Seymour said PTSD ruins lives, is difficult to treat, and MDMA can be effective through psychedelic-assisted therapy.
Caution over evidence and safety
The U.S. Food and Drug Administration rejected medicinal MDMA approval in 2024, saying evidence was insufficient to establish that it was safe or effective.
Expanding treatment options
Supporters of supervised access
Seymour said New Zealand was committed to expanding access to innovative treatments for serious conditions.
Caution over evidence and safety
U.S. clinical trials are continuing, indicating that the treatment remains under further evaluation before wider medicinal use.
Treatment safeguards
Supporters of supervised access
New Zealand requires psychotherapy, psychiatric supervision, a comprehensive treatment plan, and clinical administration without take-home drugs.
Caution over evidence and safety
The approval is limited to controlled clinical treatment, reflecting the need for safeguards while the treatment's evidence base develops.
- Regulator
- Medsafe, New Zealand's medicines regulator
- Approved prescribers
- Two psychiatrists
- Eligible patients
- Adults aged 18 or older with severe PTSD
- Treatment model
- MDMA-assisted treatment combined with psychotherapy
- Setting
- A controlled clinical setting under an authorized psychiatrist
- Take-home use
- Patients will not be supplied MDMA to take home
- International context
- Australia approved psychedelic use for PTSD and treatment-resistant depression in 2023; New Zealand is described as the second country to approve MDMA for PTSD
- U.S. position
- The FDA rejected medicinal MDMA approval in 2024, citing insufficient evidence of safety and effectiveness
